Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes
Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes
批准号:
10678361
负责人:
Mitchell L Leibowitz
金额:
$6.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2026-06-30
关键词:
AffectAgeApoptosisApoptoticBiological AssayBiological MarkersCRISPR/Cas technologyCancer PatientCancer cell lineCell CycleCell DeathCell Death InductionCell LineCell SurvivalCellsCessation of lifeChromosomal DuplicationChromosomesClonalityClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesComplexCytotoxic agentDNADNA DamageDNA Double Strand BreakDNA RepairDNA Sequence AlterationDNA Sequence RearrangementDana-Farber Cancer InstituteDataDevelopmentDouble MinutesEffectivenessElementsEncyclopediasEnzymesEvaluationEventExcisionFutureGene RearrangementGene TargetingGenesGenomeGenomicsGuide RNAHourHumanImmunotherapyInstitutionInvestigationJournalsKnock-outMalignant NeoplasmsMeasuresMediatingMedicalMentorsMethodsModalityMutateMutationNatural Killer CellsNormal CellNucleic AcidsOperative Surgical ProceduresOutcomePathway interactionsPatientsPeer ReviewPredispositionProteinsPublicationsRadiation therapyResearchResistanceScientistSeriesSiteStainsSystemTherapeuticTissuesToxic effectTrainingUnited StatesVariantcancer cellcancer genomecancer genomicscancer therapycancer typecareercell killingcell typechemotherapychromosome losschromosome missegregationchromothripsiscomputational pipelinescytotoxiccytotoxicitydata repositorydesignexperienceexperimental studygenome databasegenome editinggenomic locusimprovednew therapeutic targetnext generationnovelnovel therapeuticspan-genomeprofessorrepairedresearch facultyscreeningsmall moleculesymposiumtargeted nucleasestargeted treatmenttooltumorwhole genome
中文摘要
项目总结/文摘
英文摘要
Project Summary/Abstract
Advances in understanding the cancer genome have led to the development of novel therapeutics that
target distinct alterations in protein products of cancer DNA. The resulting targeted therapies, together with
protein-targeting immunotherapies, have led to significant advances in cancer patient survival. However, not all
patients benefit from these new therapies and instead many cancers continue to be treated with DNA double-
strand break (DSB)-generating radio- and chemo- therapies.
Nucleic acid targeting approaches such as the CRISPR-Cas9 system now enable investigation of a new
modality for experimental cancer therapeutics: targeting DNA directly rather than its protein products. This
proposal is aimed at the initial investigation and evaluation of this modality.
Hypothesis: Targeted induction of DNA DSBs at multiple rearrangement junctions, specific to the cancer
genome, can lead to cancer-cell specific cytotoxicity and spare damage to healthy tissue.
Specific Aim 1. Characterize the landscape of cancer-specific Cas9-targetable genomic sites across
cancers and cancer cell lines. In this aim, a computational pipeline will be developed to characterize the spectrum
of Cas9-targetable genome alterations across the Cancer Cell Line Encyclopedia and Pan-Cancer Analysis of
Whole Genomes databases of over 300 cancer cell lines and 2500 cancer genomes. Sequence features that
may affect target effectiveness in cancer therapy will be characterized, including target clonality, target copy
number, and the distribution of targetable genomic alterations across cancer types. This pipeline will become a
publicly available tool to generate lists of Cas9-targetable rearrangement breakpoints for use in future studies.
Aim 2. Develop methods to induce cytotoxicity in cancer cells using Cas9 targeted to cancer-specific
DNA rearrangement breakpoints. In a series of proof-of-principle experiments, this aim will assess whether Cas9
can induce targeted cell death through targeting DNA breaks to either single highly amplified sites or several
unique sites in the cancer neo-genome and whether this generates toxicity in healthy tissue.
Aim 3. Identify protein factors responsible for resistance or sensitivity to Cas9-mediated DNA damage:
This aim will comprise a CRISPR knockout screen to discover proteins that affect cell sensitivity to multiple Cas9-
induced DNA breaks.
This proposal will provide training in cancer genomics and targeted therapeutics under the guidance of
Professor Matthew Meyerson at Dana-Farber Cancer Institute, who is experienced in both fields. In addition to
experimental and computational research, the applicant will present results at conferences, train future scientists,
and interact with colleagues and mentors in the cancer genomics, genome editing, and cancer therapeutics
fields. The planned research is intended to culminate in publication in peer-reviewed journals. Ultimately, this
training should prepare the applicant for a career as research faculty at a United States research institution.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: